Abstract
Lianhua Qingwen capsule/granule is an innovative Chinese medicine developed under the guidance of the traditional Chinese medicine (TCM) collateral disease theory. It has the effect of "clearing heat and removing toxin, ventilating the lungs and discharging heat". In 2003, it was approved as a new drug by the China National Medical Products Administration, through expedited approval during severe acute respiratory syndrome, and now, it has become a representative proprietary Chinese medicine for the treatment of infectious diseases of the respiratory system. Pharmacodynamic studies have revealed that Lianhua Qingwen has broad-spectrum antiviral, antibacterial and anti-inflammatory, antipyretic, cough-relieving, and immunoregulation effects. Clinically it has been used in the treatment of communicable and infectious respiratory diseases such as Coronavirus Disease 2019, influenza, colds, pulmonary infections, etc. and has achieved remarkable curative effects, showing the important clinical guidance of the TCM collateral disease theory.
